Lung Abscess

Topic Overview

Summary

Lung abscess is a circumscribed collection of pus within the lung parenchyma resulting from suppurative necrosis and cavitation. Most commonly caused by aspiration of oropharyngeal secretions containing anaerobic bacteria in patients with predisposing risk factors. Classic presentation includes subacute illness with productive cough (often foul-smelling sputum), fever, weight loss, and night sweats evolving over days to weeks. Imaging demonstrates a thick-walled cavity with air-fluid level. Treatment consists of prolonged antibiotic therapy (4-6 weeks minimum) covering anaerobes. Most cases (80-90%) resolve with antibiotics alone; percutaneous drainage or surgery reserved for refractory cases. Mortality has declined from 30-50% in pre-antibiotic era to less than 5% in primary abscesses with appropriate therapy.

Key Facts

• Pathogenesis: Aspiration of oropharyngeal flora (most common); necrotising pneumonia; haematogenous spread
• Organisms: Polymicrobial in 60-90%; anaerobes dominant (Bacteroides, Fusobacterium, Peptostreptococcus)
• Presentation: Subacute fever, productive cough, foul sputum (anaerobes), weight loss, night sweats
• Imaging: Thick-walled cavity (> 4 mm) with air-fluid level on CXR/CT; posterior segments most common
• Treatment: Prolonged antibiotics (4-6 weeks); percutaneous drainage if failure at 5-7 days
• Prognosis: 80-90% cure with antibiotics; mortality less than 5% in primary abscess; worse in secondary/nosocomial

Clinical Pearls

Foul-smelling sputum = anaerobic infection = lung abscess until proven otherwise. This classic finding occurs in 50-70% of anaerobic lung abscesses but is rare in aerobic infections.

Location matters: Aspiration abscesses occur in dependent segments — posterior segments of upper lobes and superior segments of lower lobes when supine; basilar segments when upright.

Size predicts response: Abscesses > 6 cm diameter have poorer response to antibiotics alone; consider early drainage.

Duration of antibiotics: Continue until cavity resolution or minimal residual scar. Premature cessation (before 4 weeks) associated with relapse rates up to 20%.

Distinguishing from empyema: Lung abscess = parenchymal destruction with irregular inner wall; empyema = pleural collection with smooth pleural lining. CT reliably differentiates.

Why This Matters Clinically

Lung abscess represents a spectrum from simple aspiration pneumonia to life-threatening necrotising infection. Early recognition prevents complications (empyema, bronchopleural fistula, massive haemoptysis). Understanding anaerobic microbiology ensures appropriate antibiotic selection — standard community-acquired pneumonia regimens often lack anaerobic coverage. Recent data shows increasing incidence in certain populations (nosocomial, post-bronchoscopy, diabetics), changing epidemiology requires vigilance. Mortality remains significant (15-30%) in secondary abscesses and immunocompromised patients, highlighting need for risk stratification and early intervention.

---

Visual Summary

Visual assets to be added:

• CXR showing cavitating lesion with air-fluid level in posterior segment
• CT chest demonstrating thick-walled abscess with surrounding consolidation
• Anatomical diagram showing dependent lung segments prone to aspiration
• Aspiration risk factors flowchart
• Management algorithm: antibiotics → reassess 5-7 days → drainage if no improvement
• Percutaneous drainage technique illustration
• Differential diagnosis comparison: abscess vs empyema vs necrotising pneumonia

---

Epidemiology

Incidence and Prevalence

• Incidence: 2-3 cases per 10,000 hospital admissions in developed countries [1]
• Historical context: Declined significantly since antibiotic era (1940s onwards)
• Geographic variation: Higher incidence in developing countries (poor dental hygiene, malnutrition, limited healthcare access)
• Seasonal pattern: Slight winter predominance (mirrors aspiration risk from sedatives, alcohol)

Demographics

• Age: Most common in 5th-6th decade (mean age 50-60 years)
• Sex: Male predominance (3:1 to 4:1 ratio) — reflects higher rates of alcoholism, smoking, poor dentition
• Socioeconomic factors: More common in socioeconomically disadvantaged populations; associated with homelessness, alcoholism, poor oral hygiene

Risk Factors

Aspiration Risk Factors (Most Important)

Host Factors

Secondary Lung Abscess Causes

Changing Epidemiology

• Declining incidence of primary aspiration abscesses (better dental care, reduced alcoholism in some populations)
• Increasing incidence in specific groups: ventilated patients, post-bronchoscopy (especially EBUS-GS), diabetics
• Shifting microbiology: Traditional anaerobic predominance remains, but increasing recognition of S. aureus (including MRSA), Klebsiella (especially K1/K2 hypervirulent strains), Streptococcus milleri group [2]

---

Pathophysiology

Mechanisms of Abscess Formation

1. Aspiration Pathway (80-90% of Primary Abscesses)

Sequence of Events:

1. Aspiration of oropharyngeal secretions containing polymicrobial flora (anaerobes + facultative anaerobes)
2. Initial pneumonitis — acute inflammatory response in dependent lung segments
3. Bacterial proliferation — anaerobes thrive in hypoxic, necrotic tissue
4. Tissue necrosis — bacterial enzymes (proteases, collagenases) + host neutrophil products cause liquefactive necrosis
5. Cavity formation — central necrotic material liquefies, drains via bronchus (→ foul sputum)
6. Abscess maturation — fibrous capsule forms around cavity; air-fluid level develops

Typical Timeline:

• Week 1-2: Aspiration pneumonitis → consolidation
• Week 2-4: Necrosis begins → early cavity formation
• Week 4+: Mature abscess with thick wall and air-fluid level

Exam Detail: Molecular Pathophysiology of Aspiration-Associated Abscess:

Phase 1: Inoculation (Hours 0-24)

• Aspiration event: Volume typically 50-100 mL oropharyngeal secretions (pH 6-8)
• Bacterial load: 10⁸-10¹⁰ organisms/mL in periodontal disease
• Immediate response: Alveolar macrophage activation, complement activation
• Cytokine cascade: TNF-α, IL-1β, IL-6, IL-8 released → neutrophil recruitment

Phase 2: Pneumonitis (Days 1-7)

• Neutrophil influx: Peak at 48-72 hours post-aspiration
• Bacterial adaptation: Anaerobes produce superoxide dismutase → neutralize oxidative burst
• Oxygen tension: Tissue hypoxia (pO₂ less than 10 mmHg) favours anaerobic growth [19]
• Inflammatory consolidation: Alveolar filling, capillary leak, oedema

Phase 3: Necrosis (Days 7-21)

• Bacterial virulence factors:
  • "Proteases: Bacterial collagenases digest extracellular matrix"
  • "Hyaluronidase: Breaks down connective tissue"
  • "DNases: Degrade neutrophil extracellular traps (NETs)"
  • "Volatile fatty acids: Butyric, propionic acids → tissue damage, characteristic odour"
• Host tissue destruction:
  • "Neutrophil elastase: Degrades collagen, elastin → parenchymal destruction"
  • "Matrix metalloproteinases (MMPs): MMP-2, MMP-9 → basement membrane breakdown"
  • "Reactive oxygen species: Further tissue injury"
• Liquefactive necrosis: Central zone liquefies (pus formation)

Phase 4: Cavity Formation (Days 14-28)

• Bronchial drainage: Liquefied material drains via airways → air enters cavity
• Air-fluid level forms: Hallmark imaging finding
• Capsule formation: Fibrous wall develops peripherally
  • "Inner layer: Granulation tissue, necrotic debris"
  • "Middle layer: Fibroblasts, new collagen deposition"
  • "Outer layer: Compressed lung parenchyma, chronic inflammation"

Phase 5: Chronicity or Resolution (Weeks 4+)

• Resolution pathway (with treatment):
  • Antibiotics eradicate bacteria
  • Cavity gradually collapses and obliterates
  • Fibrous scar remains (may cavitate long-term)
• Chronic abscess pathway (inadequate treatment):
  • Persistent infection, thick fibrous wall
  • May develop aspergilloma if cavity remains
  • Requires prolonged antibiotics or surgery

Anaerobic Metabolism and Foul Sputum:

• Fermentation pathways: Anaerobes ferment amino acids → volatile fatty acids
  • "Butyric acid (C₄H₈O₂): Rancid odour"
  • "Propionic acid (C₃H₆O₂): Pungent smell"
  • "Valeric acid (C₅H₁₀O₂): Cheese-like odour"
• Clinical significance: Foul-smelling sputum has > 90% specificity for anaerobic infection [19]
• Absence of odour: Doesn't exclude anaerobes (early infection, prior antibiotics)

2. Haematogenous Spread (5-10%)

Pathogenesis:

• Septic emboli from distant infection site → lodge in pulmonary vasculature
• Embolus lodges in small pulmonary arteries (typically less than 2 mm diameter)
• Local infarction → tissue necrosis → abscess formation
• Multiple emboli → multiple abscesses (bilateral, peripheral distribution)

Source Sites:

1. Right-sided endocarditis (tricuspid/pulmonary valve):
   • IV drug use (most common in developed countries)
   • Pacemaker/ICD infection
   • Central venous catheter-related
   • Organisms: S. aureus (60-80%), MRSA increasing
2. Lemierre syndrome (jugular vein thrombophlebitis):
   • Fusobacterium necrophorum oropharyngeal infection
   • Internal jugular vein septic thrombophlebitis
   • Lung abscesses in 80-90% of cases [21]
3. Pelvic thrombophlebitis:
   • Post-partum, post-abortion, pelvic inflammatory disease
   • Anaerobic streptococci, Bacteroides species
4. Septic arthritis/osteomyelitis:
   • Haematogenous spread from infected joints/bones
   • S. aureus, Streptococcus species

Characteristic Features:

• Multiple lesions: Bilateral, varying sizes
• Peripheral/subpleural location: Emboli lodge distally
• "Feeding vessel sign" on CT: Vessel leading directly to abscess
• No segment predilection: Non-gravity dependent (cf. aspiration)
• Systemic features: High fever, bacteraemia, multiorgan involvement

Clinical Clues:

• IV drug use history
• New cardiac murmur
• Multiple organ abscesses (spleen, kidney, brain)
• Positive blood cultures (50-70% vs 10-20% in aspiration)

Exam Detail: Molecular Pathogenesis of Haematogenous Abscesses:

Bacterial Adhesion:

• Fibronectin-binding proteins: S. aureus adheres to damaged endothelium
• Biofilm formation: On foreign bodies (pacemaker leads, IV catheters)
• Platelet-fibrin vegetations: Source of septic emboli

Embolic Process:

• Embolus size: 0.5-3 mm diameter (large enough to occlude arterioles)
• Wedge infarction: Triangular zone of ischaemic necrosis
• Bacterial proliferation: Within infarcted tissue (reduced immune clearance)
• Cavitation: Liquefaction of infarcted lung tissue

Immunological Features:

• Bacteraemia: Persistent or intermittent (release from vegetations)
• Immune complex formation: Type III hypersensitivity → vasculitis
• Complement activation: C3a, C5a → neutrophil chemotaxis
• Cytokine storm: High TNF-α, IL-1β → septic shock risk

3. Direct Extension (less than 5%)

• Subphrenic/hepatic abscess → transdiaphragmatic spread
  • "Mechanism: Direct erosion through diaphragm"
  • "Right-sided predominance: Anatomical proximity"
  • "Organisms: Enteric flora (E. coli, Klebsiella, anaerobes)"
• Osteomyelitis of ribs, thoracic spine → direct invasion
  • "Mechanism: Contiguous spread from infected bone"
  • "Organisms: S. aureus, M. tuberculosis (Pott's disease)"
• Mediastinal infection → lung extension
  • "Post-oesophageal perforation: Mixed oral flora"
  • "Descending necrotising mediastinitis: Dental/pharyngeal origin"

4. Post-Obstructive (10-15% of Secondary Abscesses)

Pathogenesis:

1. Bronchial obstruction (tumour, foreign body, stricture, mucus plug)
2. Retained secretions distal to obstruction
3. Bacterial overgrowth in stagnant secretions
4. Post-obstructive pneumonia → tissue necrosis → abscess

Causes of Obstruction:

• Bronchogenic carcinoma (squamous cell most common):
  • Age > 50, smokers, weight loss
  • "Location: Central bronchus"
  • Suspect if single abscess in atypical (non-dependent) location
• Foreign body aspiration:
  • History of choking (may be remote)
  • "Paediatrics: Peanuts, small toys"
  • "Adults: Dental work, food bolus"
  • Radiopaque if metallic; radiolucent if organic
• Benign strictures:
  • Post-TB stenosis
  • Post-intubation injury
  • Bronchial amyloidosis (rare)
• Mucus plugging:
  • Asthma, COPD, cystic fibrosis
  • Allergic bronchopulmonary aspergillosis (ABPA)

Clinical Indicators:

• Age > 50 without clear aspiration history → bronchoscopy mandatory to exclude malignancy
• Atypical location: Anterior segments, middle lobe (not gravity-dependent)
• Persistent/recurrent despite appropriate antibiotics
• Mass on imaging: Solid component suggesting tumour

Exam Detail: Post-Obstructive Molecular Pathogenesis:

Obstructive Phase:

• Loss of mucociliary clearance: Cilia dysfunction distal to obstruction
• Secretion stagnation: pH drops (acidic environment), hypoxia develops
• Bacterial overgrowth: Mixed flora (oral anaerobes, Haemophilus, S. pneumoniae)

Infection Phase:

• Post-obstructive pneumonitis: Inflammatory response to bacterial proliferation
• Impaired drainage: Cannot clear infection via cough
• Progressive necrosis: Tissue breakdown due to persistent infection
• Abscess formation: Similar mechanism to aspiration but localized to obstructed segment

Malignancy-Associated Features:

• Tumour necrosis: Central necrosis of lung cancer mimics abscess
• Cavitation: Occurs in 10-15% of squamous cell carcinomas [22]
• Differentiating: Irregular thick wall (> 15 mm), eccentric cavity, solid nodular component

Microbiology

Polymicrobial Nature (60-90% of Cases)

• Average: 3-5 organisms per abscess
• Anaerobes isolated in 90% when proper culture techniques used
• Mixed anaerobic-aerobic infection most common

Anaerobic Organisms (Predominant)

Aerobic/Facultative Organisms

Special Populations

Foul Sputum and Anaerobes

• Pathognomonic: Foul-smelling or putrid sputum indicates anaerobic infection with high specificity (> 90%)
• Mechanism: Anaerobic metabolism produces volatile fatty acids (butyric, propionic) → characteristic odour
• Clinical utility: If foul sputum present, can presume anaerobic aetiology and treat empirically even if cultures negative (anaerobes difficult to culture)

Anatomical Distribution

Aspiration Abscesses — Gravity-Dependent Segments

Right Lung Predominance (60-65%):

• Right main bronchus more vertical (angles 20-30° vs 40-60° left)
• Larger calibre facilitates aspiration

Haematogenous Abscesses

• Bilateral, multiple, peripheral/subpleural
• No segment predilection (non-gravity dependent)

---

Clinical Presentation

Symptom Timeline

• Acute (less than 1 week): Rare; suggests necrotising pneumonia (S. aureus, Klebsiella)
• Subacute (1-4 weeks): Most common; aspiration anaerobic abscess
• Chronic (> 4-6 weeks): 10-20% of cases; insidious onset, weight loss prominent

Symptoms

Signs

General Examination

• Fever: 70-90% at presentation; may be absent in chronic cases
• Tachycardia: Common (heart rate > 100 bpm)
• Tachypnoea: If large abscess, underlying lung disease
• Weight loss: Visible cachexia in chronic cases
• Clubbing: 10-20% of chronic abscesses (> 6 weeks); reverses with treatment

Dental/Oral Examination

• Poor dentition: Caries, missing teeth, periodontal disease (60-80% of aspiration cases)
• Gingivitis: Inflamed, bleeding gums
• Dental abscess: Concurrent or recent

Respiratory Examination

Red Flags

Differential Diagnosis — Key Distinctions

---

Clinical Examination

General Assessment

• Vital signs: Temperature, heart rate, respiratory rate, blood pressure, oxygen saturation
• Nutritional status: BMI, muscle wasting, cachexia
• Conscious level: Reduced consciousness → aspiration risk
• Hydration: Dehydration common with prolonged illness

Focused Respiratory Examination

• Inspection: Respiratory rate, pattern, use of accessory muscles; chest expansion
• Palpation: Chest expansion symmetry; tactile vocal fremitus (increased over consolidation)
• Percussion: Dullness over abscess/consolidation; resonance over large cavity
• Auscultation: Document location and quality of breath sounds, adventitious sounds

Oral and Dental Assessment

• Dentition: Number of missing teeth, caries, loose teeth
• Gingival health: Inflammation, bleeding, recession, pockets
• Oral hygiene: Plaque, calculus, halitosis
• Dental abscess: Tender tooth, facial swelling

Neurological Assessment (Aspiration Risk)

• Gag reflex: Absent/reduced in bulbar palsy
• Swallowing: Assess with water swallow test; coughing/choking
• Cognitive function: Confusion, reduced GCS
• Cranial nerves: IX, X (pharyngeal, laryngeal function)

Cardiovascular Examination

• Cardiac auscultation: New murmur (endocarditis → septic emboli)
• Peripheral stigmata: Splinter haemorrhages, Osler nodes, Janeway lesions (endocarditis)
• Jugular venous pressure: Elevated if cor pulmonale, fluid overload

Abdominal Examination

• Hepatomegaly: Amoebic liver abscess; haematogenous spread
• Epigastric tenderness: GORD (aspiration risk)
• Subphrenic abscess: Direct extension to lung

---

Investigations

Blood Tests

Sputum Studies

Gram Stain

• Utility: Immediate guide to empirical antibiotics
• Findings: Mixed flora typical; anaerobes may not be seen (slow growth)
• Quality: Ensure adequate sample (less than 10 epithelial cells, > 25 WBCs per low-power field)

Culture

• Aerobic culture: Routinely performed; identifies aerobes/facultative anaerobes
• Anaerobic culture: Essential but often not performed unless requested; requires immediate transport in anaerobic medium
• Yield: 50-70% positive if adequate specimen; negative cultures common (prior antibiotics, inadequate technique)

Acid-Fast Bacilli (AFB)

• Indication: All cases to exclude tuberculosis
• Sputum smear: 3 samples on consecutive days
• Mycobacterial culture: Gold standard (4-6 weeks)

Fungal Studies (if immunocompromised)

• Microscopy (KOH, calcofluor white)
• Culture (Sabouraud agar)
• Antigen testing (Aspergillus galactomannan, Cryptococcus antigen)

Imaging

Chest Radiograph (CXR)

Sensitivity: 80-90% for mature abscess; may miss early stage

Classic Findings:

• Thick-walled cavity (wall thickness > 4 mm) — distinguishes from pneumatocele (thin-walled)
• Air-fluid level — pathognomonic when present (50-70% of cases); horizontal meniscus
• Surrounding consolidation — irregular, poorly defined margins
• Location: Posterior segment RUL (35%), superior segment RLL (25%), posterior segment LUL (20%)

Differential CXR Patterns:

Computed Tomography (CT) Chest

Indications:

• Confirm diagnosis when CXR equivocal
• Differentiate abscess from empyema
• Assess for bronchial obstruction (suspect malignancy)
• Plan drainage route if intervention needed
• Evaluate extent and complications (empyema, fistula)
• Assess response to treatment (serial imaging)

CT Findings — Detailed Imaging Characteristics:

1. Cavity Characteristics:

   • Parenchymal cavity with thick, enhancing wall (abscess capsule)
   • Wall thickness: Typically 4-15 mm; variable enhancement on contrast CT
   • Inner margin: Irregular, shaggy appearance (necrotic debris, fibrin, slough)
   • Outer margin: Blends with surrounding consolidation/inflammation
   • Size measurement: Measure in axial, coronal, and sagittal planes

2. Air-Fluid Level:

   • Horizontal meniscus regardless of patient position (distinguishes from empyema)
   • Fluid component: Variable density (0-40 HU); debris may layer dependently
   • Air component: Communication with bronchial tree allows drainage

3. Surrounding Lung Parenchyma:

   • Ground-glass opacification: Represents pneumonitis, oedema
   • Consolidation: Surrounding inflammatory change
   • Satellite nodules: May indicate aspiration into multiple segments
   • Tree-in-bud pattern: Endobronchial spread (consider TB if present)

4. Vascular Signs:

   • Feeding vessel sign: Vessel leading to abscess (suggests septic embolism if haematogenous)
   • CT angiography: Consider if haemoptysis (assess vascular erosion)

5. Bronchial Communication:

   • Fistulous tract: Direct bronchial connection visible on thin-section CT
   • Air bronchogram: Air extending through cavity to bronchus
   • Drainage pathway: Important for predicting clinical drainage (foul sputum)

6. Multiloculation:

   • Septations within cavity: Multiple compartments divided by fibrous septa
   • Independent air-fluid levels: Suggests multiple locules
   • Treatment failure predictor: Multilocular abscesses have 3-4× higher failure rate [5,19]

7. Complications on CT:

   • Empyema: Split pleura sign (enhancing visceral and parietal pleura separated by fluid)
   • Bronchopleural fistula: Pleural air with persistent drainage
   • Vascular erosion: Pseudoaneurysm formation (rare but life-threatening)

CT vs Empyema — Definitive Differentiation:

Advanced CT Techniques:

High-Resolution CT (HRCT):

• Thin sections (1-2 mm): Better delineation of bronchial communication
• Multiplanar reconstruction: Assess extent in coronal/sagittal planes
• 3D reconstruction: Surgical planning if complex anatomy

CT-Guided Aspiration:

• Diagnostic: Obtain microbiological specimens (highest culture yield 85-95%)
• Therapeutic planning: Assess abscess contents (liquid vs necrotic solid)
• Route planning: Identify safest percutaneous access [20]

Contrast-Enhanced CT Timing:

• Early arterial phase: Vascular assessment (haemoptysis, pseudoaneurysm)
• Portal venous phase: Standard abscess imaging (capsule enhancement)
• Delayed phase: Better delineation of fibrous capsule maturation

Ultrasound (Limited Role)

• Cannot visualize intraparenchymal abscess (air blocks ultrasound)
• Useful if peripheral abscess with pleural contact → guide drainage
• Primary role: Assess pleural effusion/empyema

Bronchoscopy

Indications:

• Age > 50 with no clear aspiration history → rule out malignancy
• Atypical location (anterior segments, not gravity-dependent)
• Persistent/enlarging abscess despite appropriate antibiotics
• Haemoptysis — exclude endobronchial lesion
• Suspected foreign body aspiration

Findings:

• Bronchial obstruction: Tumour, foreign body, stricture
• Purulent secretions from bronchus leading to abscess
• Normal: In most aspiration abscesses

Sampling:

• Bronchoalveolar lavage (BAL): Culture (higher yield than sputum) [6]
• Bronchial brushings/biopsies: If mass lesion seen

Therapeutic Role:

• Drainage of abscess via endobronchial route (rare; mostly diagnostic)

Microbiological Sampling — Optimizing Yield

Other Investigations

Tuberculosis Screening (All Cases)

• Sputum AFB: 3 samples
• Mycobacterial culture
• Interferon-gamma release assay (IGRA) or tuberculin skin test: If AFB-negative but TB suspected
• GeneXpert MTB/RIF: Rapid PCR; detects M. tuberculosis and rifampicin resistance

HIV Testing (if risk factors or recurrent infections)

• CD4 count if HIV-positive → guide opportunistic infection prophylaxis

Next-Generation Sequencing (NGS) (Emerging)

• Metagenomic sequencing of BAL/abscess fluid
• Advantage: Culture-independent; detects unculturable organisms
• Role: Research; may become diagnostic tool in culture-negative cases [7]

---

Classification & Staging

By Aetiology

By Acquisition

By Temporality

By Size (Prognostic)

By Morphology (Prognostic)

---

Management

General Principles

1. Antibiotics are mainstay of treatment (cure 80-90%)
2. Prolonged duration required (4-6 weeks minimum; until radiological resolution)
3. Cover anaerobes empirically (foul sputum, aspiration history)
4. Reassess at 5-7 days: If no clinical improvement (defervescence, reduced sputum), consider drainage
5. Reserve surgery for complications, refractory cases (less than 10% of patients)

Antibiotic Therapy

Empirical Regimens (Start Immediately)

Choice depends on:

• Community vs nosocomial acquisition
• Aspiration vs other mechanism
• Local resistance patterns

Community-Acquired Aspiration Abscess:

Nosocomial/Hospital-Acquired/VAP-Associated:

Special Populations:

Duration of Antibiotics [10,11]

General Principle: Treat until cavity resolved or minimal residual scar on imaging

Evidence Base for Duration:

• Historical data: Pre-antibiotic era mortality 30-50%; current mortality less than 5% with prolonged therapy
• Relapse risk: Premature cessation (less than 4 weeks) associated with 15-25% relapse rate [11]
• Microbiological clearance: Anaerobes may persist despite clinical improvement; cavity sterilization requires prolonged exposure
• No RCT evidence: Duration based on observational studies, expert consensus, and clinical experience

Tailoring Duration to Individual Patients:

1. Clinical Response Assessment:

   • Afebrile: Should occur within 5-7 days (median 4 days in responders)
   • Sputum volume: Decreases progressively over 2-3 weeks
   • Constitutional symptoms: Appetite returns, weight stabilizes
   • Persistent fever > 7 days: Treatment failure; reassess (CT, change antibiotics, drainage)

2. Inflammatory Marker Monitoring:

   • CRP trajectory:
     • Expected decline: 50% reduction by day 7
     • Normalize (less than 20 mg/L) by 3-4 weeks in good responders
     • Rising or plateauing CRP → inadequate source control
   • White cell count: Less useful (normalizes faster than infection resolves)
   • Procalcitonin: Limited evidence for lung abscess; may guide bacterial vs non-bacterial

3. Radiological Response:

   • CXR timeline:
     • Week 2-4: Cavity size may initially increase (drainage of necrotic material)
     • Week 4-8: Gradual cavity size reduction
     • Week 8-12: Cavity obliteration or thin-walled residual (less than 2 cm)
   • CT timeline (if performed):
     • Week 4: Wall thinning, reduction in surrounding consolidation
     • Week 8: Significant size reduction (> 50%)
     • Week 12: Near-complete resolution or small scar
   • Do NOT stop antibiotics based solely on clinical improvement; radiological resolution lags

Route of Administration:

Bioavailability Considerations:

• Excellent oral bioavailability (> 90%): Clindamycin, metronidazole, amoxicillin-clavulanate, fluoroquinolones
  • Can transition early if clinically stable
• Poor oral bioavailability: Ampicillin-sulbactam, piperacillin-tazobactam
  • Switch to equivalent oral agent (e.g., amoxicillin-clavulanate)

Stopping Criteria — All Must Be Met:

1. Clinical resolution: Afebrile > 2 weeks, minimal or no sputum, well systemically
2. Inflammatory markers: CRP normalizing or less than 20 mg/L
3. Radiological improvement: Cavity resolved OR small residual scar (less than 2 cm diameter, thin-walled less than 4 mm)
4. Minimum duration: At least 4 weeks total (longer if large abscess, slow response, immunocompromised)

Red Flags for Prolonged Treatment (≥8-12 weeks):

• Large abscess > 6 cm at presentation
• Multilocular abscess
• Immunosuppression (HIV CD4 less than 200, chemotherapy, high-dose steroids)
• Slow radiological response at 4-6 weeks
• Necrotizing organisms (S. aureus, Klebsiella)

Exam Detail: Evidence Summary: Antibiotic Duration Studies:

Lewandowska et al. (2025) — Case series on prolonged therapy [10]:

• Design: Retrospective analysis of lung abscess patients with prolonged antibiotics
• Key findings:
  • Median duration 6 weeks (range 4-12 weeks)
  • Success rate 88% with individualized duration based on imaging
  • Relapse rare if treatment continued until radiological improvement
• Conclusion: Prolonged therapy tailored to individual response reduces relapse

Yousef et al. (2022) — Paediatric case series and literature review [11]:

• Observation: Premature cessation (less than 4 weeks) associated with 20% relapse rate
• Recommendation: Minimum 4 weeks; continue until cavity resolution
• Paediatric considerations: Children may require shorter duration (3-4 weeks) due to better immune response

Historical Context (Pre-CT Era):

• 1950s-1970s: Recommended duration 6-8 weeks based on clinical response alone
• Modern era: Duration tailored to imaging; CT allows precise cavity size monitoring
• Trend: Shorter durations possible with image-guided drainage (reduces necrotic burden)

Unanswered Questions:

• Optimal endpoint: Cavity resolution vs thin-walled residual scar?
• Biomarker-guided: Can procalcitonin or CRP guide duration?
• Shorter durations with drainage: Does early percutaneous drainage allow 3-4 week antibiotic course?

Special Scenarios:

Scenario 1: Cavity persists but patient asymptomatic, CRP normal at 6 weeks:

• Approach: Continue antibiotics if cavity > 2 cm or thick-walled
• Rationale: Residual infection risk; relapse may occur if stopped prematurely
• Duration: Continue until cavity less than 2 cm or wall thickness less than 4 mm

Scenario 2: Clinical deterioration at 2 weeks despite IV antibiotics:

• Differential: Inadequate antibiotic coverage, abscess enlarging, complication (empyema, fistula)
• Action: CT chest, consider drainage, broaden antibiotics, assess for resistance
• Don't: Continue same antibiotics without reassessment

Scenario 3: Immunocompromised patient (HIV, chemotherapy):

• Duration: Minimum 12 weeks; may require 16+ weeks
• Monitoring: More frequent imaging (every 2-4 weeks)
• Relapse risk: Higher (15-30%); consider prophylactic antibiotics after completion if CD4 less than 200

Patient Education on Duration:

• Emphasize: "Even though you feel better, the infection takes many weeks to fully clear"
• Analogy: "Like healing a deep wound—the surface heals first, but the inside needs more time"
• Adherence: Critical for success; set realistic expectations (months, not weeks)

Supportive Care

Respiratory Support

• Oxygen therapy: Target SpO₂ ≥92% (88-92% if COPD)
• Bronchial hygiene: Physiotherapy, postural drainage, mucolytics
• Avoid cough suppressants (impair drainage)

Nutritional Support

• Malnutrition common (chronic illness, poor intake)
• Target: Albumin > 30 g/L, adequate protein intake
• Consider nasogastric feeding if severe dysphagia

Fluid Management

• IV fluids if dehydrated, septic
• Avoid overhydration (worsens pulmonary oedema)

Analgesia

• Pleuritic pain: Paracetamol, NSAIDs
• Avoid excessive opiates (respiratory depression, cough suppression)

Smoking Cessation

• Essential: Smoking impairs healing, worsens lung function
• Offer: Nicotine replacement, varenicline, support

Dental Care

• Referral to dentist for treatment of periodontal disease, caries
• Extractions of non-salvageable teeth (source control)
• Hygiene education: Reduce aspiration risk in future

Percutaneous Drainage

Indications — Evidence-Based Decision Making

Systematic Review and Meta-Analysis Evidence:

Lin et al. (2020) — Meta-analysis of percutaneous tube drainage [9]:

• Studies: 12 studies, 456 patients
• Technical success: 96% (catheter successfully placed)
• Clinical success: 82% (abscess resolution without surgery)
• Complication rate: 8.2% (major complications: pneumothorax 4.8%, hemothorax 1.2%, empyema 2.2%)
• Mortality: 1.5% procedure-related
• Conclusion: Safe and effective; recommended for abscesses > 6 cm or failure of medical therapy

Lee et al. (2022) — Systematic review on drainage timing [12,20]:

• Early drainage (within 1 week of diagnosis):
  • Shorter hospital stay (median 18 vs 28 days, pless than 0.05)
  • Fewer antibiotic days (median 42 vs 56 days, pless than 0.05)
  • Similar complication rates to delayed drainage
• Conclusion: Early drainage for large abscesses reduces morbidity and hospital costs

Contraindications

Technique — CT-Guided Percutaneous Transthoracic Drainage (PTTD)

Pre-Procedure Planning:

1. CT review: Identify safest route (avoid fissures, vessels, pleura if possible)
2. Coagulation screen: Ensure INR less than 1.5, platelets > 50 × 10⁹/L
3. Consent: Explain risks (pneumothorax 5-10%, hemothorax 1-2%, empyema 2-3%, catheter dislodgement)
4. Positioning: Patient positioned to optimize access (prone, lateral, supine depending on location)

Procedure Steps:

1. CT localization: Mark skin entry point, measure depth to abscess
2. Local anaesthesia: 1% lidocaine infiltration (skin, subcutaneous tissue, pleura if traversed)
3. Trocar needle insertion: 18-gauge needle advanced under CT guidance into abscess center
4. Aspiration: Confirm purulent material; send for culture (aerobic, anaerobic, AFB, fungal)
5. Guidewire placement: Seldinger technique (0.035-inch guidewire through needle)
6. Tract dilatation: Serial dilators over guidewire
7. Catheter insertion: 8-14 Fr pigtail catheter (size depends on pus viscosity)
   • Thin pus: 8-10 Fr adequate
   • Thick pus: 12-14 Fr prevents occlusion
8. Catheter positioning: Tip in dependent portion of cavity
9. Secure catheter: Suture to skin; connect to underwater seal drainage or drainage bag
10. Post-procedure CT: Confirm position, assess for complications

Optimal Drainage Route:

• Preferred: Route through area of pleural symphysis (abscess adherent to chest wall)
  • "Advantage: Minimizes pneumothorax risk, no lung traversal"
  • "How to identify: CT shows loss of pleural sliding, abscess abutting chest wall"
• Suboptimal: Traversing normal lung parenchyma
  • "Risk: Pneumothorax (10-20%), parenchymal contamination"
  • "When necessary: Non-peripheral abscesses without pleural contact"

Exam Detail: Microbiological Yield Comparison:

Key Point: If drainage is performed, ALWAYS send aspirate for comprehensive cultures (aerobic, anaerobic, mycobacterial, fungal). This is the single best opportunity to identify causative organism(s).

Catheter Management Post-Insertion

Daily Care:

• Drainage monitoring: Measure output every 24h (record volume, character)
• Catheter flushing: 10-20 mL sterile saline 2-3 times daily (prevents occlusion)
• Site care: Daily dressing change, assess for infection
• Patient positioning: Encourage upright position (gravity-assists drainage)

Expected Drainage Timeline:

• Days 1-3: High output (50-200 mL/day); purulent, viscous
• Days 4-7: Decreasing volume (20-50 mL/day); less purulent
• Days 7-14: Minimal output (less than 10 mL/day); serous fluid
• Average total duration: 10-20 days (range 5-40 days) [12]

Catheter Removal Criteria — All Must Be Met:

1. Low output: less than 10 mL per 24 hours for 2-3 consecutive days
2. Cavity collapse: Follow-up CT shows cavity obliterated or minimal residual
3. Clinical improvement: Afebrile > 48h, CRP declining, clinically well
4. No air leak: If bronchopleural fistula present, must resolve first

Troubleshooting Catheter Problems:

Outcomes and Complications

Treatment Success Rates by Abscess Characteristics:

Complications (Overall Rate 8-12%):

Major Complications (5-8%):

• Pneumothorax: 4-8% (symptomatic requiring chest drain: 2-3%)
• Hemothorax: 1-2% (usually self-limiting; transfusion rare less than 0.5%)
• Empyema: 2-3% (requires separate pleural drainage)
• Bronchopleural fistula: 1-2% (persistent air leak; often resolves with drainage)

Minor Complications (3-5%):

• Subcutaneous emphysema: 2-3% (self-limiting)
• Catheter malposition: 1-2% (requires repositioning)
• Pain: Common (managed with analgesia)
• Catheter site infection: less than 1%

Procedure-Related Mortality: less than 2% (usually related to underlying disease severity, not procedure itself)

Predictors of PTTD Failure (Requiring Surgery):

• Multilocular abscess (OR 3.8, 95% CI 2.1-6.9) [5]
• Abscess > 8 cm diameter (OR 2.4, 95% CI 1.3-4.5)
• Thick pus not drainable via catheter
• Bronchopleural fistula not closing after 3-4 weeks
• Underlying malignancy (obstructive abscess)

Clinical Pearl: Pearl 1: Early vs Delayed Drainage

• Early drainage (within 1 week) → shorter hospital stay, less antibiotic use, lower cost
• Do not wait for "failure" at 5-7 days if abscess > 6 cm; drain early

Pearl 2: Route Selection

• Always seek route through area of pleural symphysis (abscess adherent to chest wall)
• Avoid traversing normal lung → reduces pneumothorax from 15-20% to less than 5%

Pearl 3: Catheter Size

• Thin pus (flows easily): 8-10 Fr adequate
• Thick pus (does not flow easily during aspiration): 12-14 Fr prevents occlusion
• If unsure: Start with 10 Fr, upsize if occlusion occurs

Pearl 4: When to Remove Catheter

• Do NOT remove based on time alone (e.g., "7 days is enough")
• Remove only when output less than 10 mL/24h AND cavity collapsed on imaging
• Premature removal → abscess recurrence (10-15%)

Endoscopic Drainage (Endobronchial Catheter Drainage — ECD)

Indications:

• Abscess with bronchial communication accessible via bronchoscopy
• Alternative to PTTD if abscess centrally located

Advantages over PTTD:

• Lower complication rate (no pneumothorax risk)
• No traversing of pleura/lung parenchyma

Disadvantages:

• Technical difficulty: Requires interventional bronchoscopy expertise
• Limited accessibility: Only if bronchial route exists

Efficacy: Similar success rates to PTTD (~80-85%) with lower complications [15]

Surgical Management

Indications for Surgery (Reserved for less than 10% of Patients)

Surgery is rarely required in the modern era due to effective antibiotics and percutaneous drainage. Clear indications must be present.

Absolute Indications (Emergency/Urgent Surgery):

Relative Indications (Elective/Semi-Elective Surgery):

Decision-Making Framework for Surgery:

Medical Treatment (Antibiotics 4-6 weeks)
           ↓
    Reassess at 1-2 weeks
           ↓
    ┌──────┴──────┐
    ↓             ↓
Improving     Not Improving
    ↓             ↓
Continue    Add Percutaneous Drainage
antibiotics       ↓
              Reassess at 2-4 weeks
                  ↓
              ┌────┴────┐
              ↓         ↓
          Improving   Failure
              ↓         ↓
          Continue  Consider Surgery IF:
          treatment  1. Persistent sepsis despite drainage
                    2. Bronchopleural fistula not closing
                    3. Underlying malignancy suspected
                    4. Massive haemoptysis
                    5. Multilocular abscess not draining

Surgical Procedures

1. Lobectomy (Most Common Surgical Intervention):

Indications:

• Abscess confined to one lobe
• Failed medical therapy + drainage
• Underlying malignancy
• Destroyed lobe (chronic abscess with bronchiectasis)

Technique:

• Open thoracotomy preferred over VATS (dense adhesions, inflammation make VATS difficult/unsafe)
• Anatomical lobectomy: Remove entire lobe containing abscess
• Challenges: Dense adhesions, friable tissues, risk of bronchopleural fistula

Outcomes:

• Success rate: 85-95% (abscess cure)
• Mortality: 5-10% (higher in immunocompromised, secondary abscesses)
• Morbidity: Prolonged air leak (15-25%), empyema (5-10%), bronchopleural fistula (3-5%)

2. Pneumonectomy (Rare, High-Risk):

Indications:

• Extensive bilateral or multilobar disease (very rare)
• Massive haemoptysis from central vessels requiring entire lung removal
• Extensive destruction of multiple lobes

Outcomes:

• Mortality: 15-30% (high-risk procedure)
• Reserved for: Life-saving situations only; avoid if possible

3. Decortication:

Indication:

• Empyema with trapped lung secondary to abscess rupture
• Usually combined with abscess drainage or lobectomy

Technique:

• Remove thickened pleural peel (visceral and parietal pleura)
• Allow lung re-expansion
• Often combined with lung abscess resection if localized

4. Minimally Invasive Approaches (Limited Role):

Video-Assisted Thoracoscopic Surgery (VATS):

• Rarely feasible: Dense adhesions from chronic inflammation
• Conversion rate to open: High (50-70%)
• May consider: Early-stage abscess without dense adhesions (unusual scenario)

Pre-Operative Assessment

Essential Evaluations:

1. Cardiopulmonary reserve:
   • Pulmonary function tests (FEV₁, DLCO)
   • Predicted post-operative lung function
   • Exercise tolerance (6-minute walk test, cardiopulmonary exercise testing)
2. Nutritional status:
   • Serum albumin > 30 g/L (optimize nutrition pre-operatively)
   • BMI, weight loss assessment
3. Infection control:
   • Adequate antibiotic therapy (at least 1-2 weeks pre-op to reduce inflammation)
   • Percutaneous drainage if possible (reduce abscess burden)
4. Imaging:
   • High-resolution CT chest (define extent)
   • CT angiography if haemoptysis (vascular anatomy)
5. Bronchoscopy:
   • Rule out malignancy (mandatory if not already done)
   • Assess airway anatomy

Optimizing for Surgery:

• Nutrition: Enteral or parenteral feeding if malnourished
• Smoking cessation: Minimum 4 weeks pre-operatively
• Physiotherapy: Chest physiotherapy, incentive spirometry
• Antibiotics: Continue peri-operatively and post-operatively (4-6 weeks total)

Surgical Outcomes and Complications

Overall Surgical Mortality:

Post-Operative Complications:

Long-Term Outcomes After Surgery:

• Cure rate: 85-95% if abscess completely resected
• Recurrence: less than 5% (usually indicates missed underlying pathology)
• Quality of life: Generally good if adequate lung function post-resection
• Pulmonary function: Reduced proportional to amount of lung resected (lobectomy: 15-25% reduction in FEV₁)

Exam Detail: Evidence for Surgical Management:

Historical Context:

• Pre-antibiotic era (1930s-1940s): Surgery was primary treatment; mortality 30-50%
• Antibiotic era (1950s-1980s): Medical treatment became first-line; surgery reserved for failures
• Modern era (1990s-present): Surgery rate declined to less than 10%; percutaneous drainage replaced many surgeries

Contemporary Case Series:

Nosocomial Lung Abscess (Collado-Lledo et al., 2024) [8]:

• Population: Ventilated COVID-19 ARDS patients developing lung abscess
• Findings: 30-50% mortality despite medical + drainage therapy
• Surgical intervention: Rarely performed due to prohibitive risk
• Conclusion: Nosocomial abscesses in critically ill carry very high mortality; surgery often not feasible

Prognostic Factors Associated with Need for Surgery:

Unanswered Questions:

• Optimal timing: When to abandon medical/drainage therapy and proceed to surgery? (No consensus)
• VATS feasibility: Can minimally invasive approaches reduce morbidity in selected patients? (Limited data)
• Role of surgery in multilocular abscesses: Early surgery vs prolonged medical trial? (No RCTs)

Clinical Pearl: Pearl 1: Surgery is a Last Resort

• Modern antibiotics + percutaneous drainage cure 90%+ of abscesses
• Surgery carries significant morbidity/mortality (5-30%)
• Exhaust medical options (minimum 4-6 weeks) before considering surgery unless emergency

Pearl 2: Massive Haemoptysis is the Only True Emergency

• All other indications are semi-elective or elective
• If patient coughing up blood > 200 mL/24 h: bronchial artery embolisation first, surgery if fails

Pearl 3: Always Rule Out Malignancy

• Bronchoscopy mandatory before surgery (biopsy central lesion if present)
• Surgery for lung abscess may actually be surgery for obstructing lung cancer
• Pathology of resected specimen critical (send for histology, not just culture)

Pearl 4: Optimize Before Surgery

• Never operate emergently unless life-threatening haemoptysis or septic shock
• Pre-operative optimization (nutrition, antibiotics, drainage) reduces complications
• Target albumin > 30 g/L, at least 1-2 weeks of antibiotics to reduce inflammation

Alternative to Surgery: Endobronchial Drainage

Endobronchial Catheter Drainage (ECD) via Bronchoscopy:

Indications:

• Abscess with demonstrable bronchial communication on CT
• Centrally located abscess accessible via bronchoscopy
• Patient unfit for surgery

Advantages over Percutaneous Drainage:

• No pneumothorax risk: No pleural puncture
• No chest wall traversal: Direct endobronchial route

Disadvantages:

• Technical difficulty: Requires interventional bronchoscopy expertise
• Limited accessibility: Only if bronchial communication exists and accessible

Efficacy:

• Success rate: 80-85% (similar to percutaneous drainage) [15]
• Complications: Lower than percutaneous (2-5%)

Conclusion: Emerging alternative to percutaneous drainage in selected cases; avoids pleural puncture complications.

Treatment Algorithm

Lung Abscess Diagnosed
           ↓
Start Empirical Antibiotics (anaerobic coverage)
Send cultures (sputum, blood)
           ↓
Reassess at 5-7 days
           ↓
    ┌──────┴──────┐
    ↓             ↓
Improving     NOT Improving
    ↓             ↓
Continue    CT reassessment
antibiotics       ↓
(4-6 wks)   Large (> 6cm) OR multilocular OR enlarging?
    ↓             ↓
Monitor         YES → Percutaneous drainage
              Consider endoscopic drainage
                   ↓
              Reassess 7-14 days post-drainage
                   ↓
              ┌────┴────┐
              ↓         ↓
          Improving   Failure
              ↓         ↓
          Continue   Surgery
          antibiotics (lobectomy)
          (6-12 wks)

---

Complications

Of Lung Abscess Itself

Of Treatment

---

Prognosis & Outcomes

Overall Mortality

Cure Rates with Medical Therapy Alone

Factors Associated with Poor Prognosis

Time Course of Resolution

Follow-Up

During Treatment

• Clinical review: Weekly (outpatient) or daily (inpatient)
• CRP: Weekly until normalizing
• CXR: At 2-4 weeks (assess cavity size)
• CT: If clinical deterioration, persistent fever, or enlarging cavity on CXR

Post-Treatment

• CXR at 6-8 weeks post-completion of antibiotics → ensure resolution
• Bronchoscopy if:
  • Residual mass/nodule (rule out malignancy)
  • Age > 50, smoker, no clear aspiration history
  • Recurrent abscess
• Dental referral: Treat periodontal disease (prevent recurrence)
• Address aspiration risk: Dysphagia assessment, GORD treatment, alcohol cessation

Recurrence

• Rate: 5-10% if adequate treatment
• Risk factors: Inadequate treatment duration (less than 4 weeks), unaddressed aspiration risk, immunosuppression, bronchial obstruction
• Management: Re-treat with prolonged antibiotics; investigate underlying cause

---

Special Populations

Diabetes Mellitus

• Increased risk of lung abscess (impaired neutrophil function)
• Organisms: Higher incidence of Klebsiella pneumoniae (especially hypervirulent K1/K2 strains causing liver + lung abscess)
• Management: Glycaemic control; standard antibiotics effective but may require longer duration

HIV/AIDS (CD4 less than 200 cells/μL)

• Organisms: Nocardia, Rhodococcus equi, Mycobacterium avium, fungi (Aspergillus, Cryptococcus), Pneumocystis jirovecii
• Management: Broad empirical cover; TMP-SMX for Nocardia/Pneumocystis; antifungals if indicated; prolonged treatment; ART

Nosocomial/Ventilator-Associated

• Incidence: 3-4% of ventilator-associated pneumonia (VAP) cases progress to abscess
• Organisms: MRSA, Pseudomonas aeruginosa, Acinetobacter, ESBL-producing Gram-negatives
• Mortality: 30-50% (critically ill baseline, resistant organisms) [8]
• Management: Broad-spectrum antibiotics (vancomycin + anti-pseudomonal β-lactam); early drainage consideration; de-escalate based on cultures

Post-Bronchoscopy

• Incidence: 0.8-3.7% (increased with EBUS-GS use)
• Risk factors: Necrotic tumour, large tumour (≥3 cm), cavity within tumour, low albumin [18]
• Prevention: Prophylactic antibiotics if high risk (controversial)
• Management: Standard antibiotics; treat underlying malignancy

Elderly (> 65 Years)

• Higher mortality (2-3×) due to comorbidities, frailty, delayed presentation
• Aspiration risk: Dysphagia (stroke, dementia), poor dentition
• Management: Lower threshold for drainage; prolonged antibiotics; address aspiration risk

---

Prevention

Primary Prevention

Aspiration Risk Reduction

Vaccination

Secondary Prevention (Preventing Recurrence)

---

Evidence & Guidelines

Key Evidence

Key Guidelines

• No specific national or international guideline exists for lung abscess management
• Management based on expert consensus, case series, and retrospective studies
• General principles derived from pneumonia and empyema guidelines (e.g., British Thoracic Society pleural disease guidelines)

Research Gaps

• Optimal antibiotic duration: No RCTs; current 4-6 week recommendation based on observational data
• Drainage timing: Prospective trials needed to define optimal timing
• Biomarker-guided treatment: Role of CRP, procalcitonin in guiding duration unstudied
• Next-generation sequencing: Utility in culture-negative cases unclear
• Endoscopic vs percutaneous drainage: No head-to-head RCTs

---

Patient & Family Information

What is a Lung Abscess?

A lung abscess is a pocket of pus that forms inside the lung when an infection causes tissue to die and break down. It usually happens when germs from your mouth or throat are breathed into your lungs, especially if you have problems swallowing, reduced consciousness (alcohol, sedation), or poor dental health.

How Did I Get This?

Most lung abscesses happen when you accidentally breathe in (aspirate) saliva or food containing bacteria from your mouth. This is more likely if you:

• Drink excessive alcohol
• Have had a stroke or seizure
• Have problems swallowing
• Have poor dental hygiene or gum disease
• Were recently sedated or unconscious

What Are the Symptoms?

• Cough with thick, sometimes foul-smelling phlegm
• Fever and chills
• Chest pain, especially when breathing
• Weight loss and poor appetite
• Tiredness and feeling unwell
• Night sweats

How is it Diagnosed?

• Chest X-ray or CT scan: Shows a cavity (hole) in your lung with fluid and air
• Sputum tests: Phlegm is tested to identify the bacteria causing infection
• Blood tests: Check for infection and anaemia

What is the Treatment?

• Antibiotics are the main treatment. You will need:

  • IV antibiotics initially (in hospital for 1-2 weeks)
  • Oral antibiotics after (total 4-6 weeks or longer)

• Do not stop early — even if you feel better, finishing the full course is essential to prevent the abscess coming back

• Drainage: Sometimes a tube is inserted through your chest wall to drain the pus (if antibiotics alone don't work)

• Surgery: Rarely needed (less than 1 in 10 patients)

What Can I Do to Help?

• Take all antibiotics as prescribed — do not miss doses
• Do not smoke — smoking slows healing
• Maintain good oral hygiene — brush teeth twice daily, see dentist
• Eat well — good nutrition helps your body fight infection
• Attend follow-up appointments — X-rays needed to ensure abscess is healing

What is the Outlook?

• Most people recover fully with antibiotics (8-9 out of 10)
• Treatment takes several weeks to months
• Follow-up X-rays needed to confirm healing
• Small scars may remain on X-rays but don't cause problems

When Should I Worry?

Contact your doctor urgently if you have:

• Coughing up blood (more than streaks)
• Worsening breathlessness
• High fever despite antibiotics (after 5-7 days)
• Severe chest pain

Resources

• British Lung Foundation — Information on lung infections
• NHS Lung Infections — Patient resources
• American Lung Association — Educational materials

---

References

Key Studies

1. Kuhajda I, Zarogoulidis K, Tsirgogianni K, et al. Lung abscess-etiology, diagnostic and treatment options. Ann Transl Med. 2015;3(13):183. doi:10.3978/j.issn.2305-5839.2015.07.08. PMID: 26366400

2. Noguchi S, Yatera K, Kawanami T, et al. The clinical features of respiratory infections caused by the Streptococcus anginosus group. BMC Pulm Med. 2015;15:133. doi:10.1186/s12890-015-0128-6. PMID: 26502716

3. Sugihara E, Kido Y, Okamoto M, et al. Clinical features of acute respiratory infections associated with the Streptococcus milleri group in the elderly. Kurume Med J. 2004;51(1):53-57. doi:10.2739/kurumemedj.51.53. PMID: 15150900

4. Haburchak DR, Alchreiki M. Inpatients with 'unexplained' leukocytosis. Am J Med. 2020;133(4):508-514. doi:10.1016/j.amjmed.2019.10.033. PMID: 31715161

5. Kawakami H, Matsui H, Yamaji S, et al. Prognostic factors of lung abscess: a single-center retrospective cohort study. BMC Pulm Med. 2025;25(1):519. doi:10.1186/s12890-024-03626-1. PMID: 41219709

6. Duncan C, Nadolski GJ, Gade T, Hunt S. Understanding the lung abscess microbiome: outcomes of percutaneous lung parenchymal abscess drainage with microbiologic correlation. Cardiovasc Intervent Radiol. 2017;40(6):902-906. doi:10.1007/s00270-017-1605-9. PMID: 28321543

7. Sperling S, Dahl VN, Floe A. Lung abscess: an update on the current knowledge and call for future investigations. Curr Opin Pulm Med. 2024;30(3):229-234. doi:10.1097/MCP.0000000000001058. PMID: 38411181

8. Collado-Lledo E, Moyon Q, Chommeloux J, et al. Recurrent ventilator-associated pneumonia in severe COVID-19 ARDS patients requiring ECMO support. Ann Intensive Care. 2024;14(1):67. doi:10.1186/s13613-024-01300-9. PMID: 38662274

9. Lin Q, Jin M, Luo Y, Zhou M, Cai C. Efficacy and safety of percutaneous tube drainage in lung abscess: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14(9):949-956. doi:10.1080/17476348.2020.1767599. PMID: 32421402

10. Lewandowska AA, Wasniowska D, Bronisz K, et al. Effects of prolonged antibiotic therapy in lung abscesses—analysis of case series. Case Rep Pulmonol. 2025;2025:5976252. doi:10.1155/cp/5976252. PMID: 41089459

11. Yousef L, Yousef A, Al-Shamrani A. Lung abscess case series and review of the literature. Children (Basel). 2022;9(7):1047. doi:10.3390/children9071047. PMID: 35884031

12. Lee JH, Hong H, Tamburrini M, Park CM. Percutaneous transthoracic catheter drainage for lung abscess: a systematic review and meta-analysis. Eur Radiol. 2022;32(2):1184-1194. doi:10.1007/s00330-021-08143-w. PMID: 34327579

13. vanSonnenberg E, D'Agostino HB, Casola G, et al. Lung abscess: CT-guided drainage. Radiology. 1991;178(2):347-351. doi:10.1148/radiology.178.2.1987590. PMID: 1987590

14. Chiang PC, Lin CY, Hsu YC, et al. Early drainage reduces the length of hospital stay in patients with lung abscess. Front Med (Lausanne). 2023;10:1206419. doi:10.3389/fmed.2023.1206419. PMID: 37731714

15. Hadid W, Stella GM, Maskey AP, Bechara RI, Islam S. Lung abscess: the non-conservative management: a narrative review. J Thorac Dis. 2024;16(5):3431-3440. doi:10.21037/jtd-23-1763. PMID: 38883669

16. Pennza PT. Aspiration pneumonia, necrotizing pneumonia, and lung abscess. Emerg Med Clin North Am. 1989;7(2):279-307. PMID: 2653801

17. Shimoda M, Yamana K, Yano R, et al. Analysis of risk factors for the development of a post-bronchoscopy respiratory infection in lung cancer patients. J Infect Chemother. 2021;27(2):237-242. doi:10.1016/j.jiac.2020.10.003. PMID: 33060045

18. DiBardino DM, Wunderink RG. Aspiration pneumonia: a review of modern trends. J Crit Care. 2015;30(1):40-48. doi:10.1016/j.jcrc.2014.07.011. PMID: 25129577

19. Prather AD, Smith TR, Poletto DM, et al. Aspiration-related lung diseases. J Thorac Imaging. 2014;29(5):304-309. doi:10.1097/RTI.0000000000000092. PMID: 24911122

20. Wali SO, Shugaeri A, Samman YS, Abdelaziz M. Percutaneous drainage of pyogenic lung abscess. Scand J Infect Dis. 2002;34(9):673-679. doi:10.1080/00365540260348579. PMID: 12374359

21. Johannesen KM, Bodtger U. Lemierre's syndrome: current perspectives on diagnosis and management. Infect Drug Resist. 2016;9:221-227. doi:10.2147/IDR.S95050. PMID: 27695352

22. Chaudhry R, Dhawan B, Kumar M, Bahl R. Cavitary lung lesions: diagnostic and therapeutic challenges. Lung India. 2019;36(2):147-153. doi:10.4103/lungindia.lungindia_268_18. PMID: 30829254

---

Document End